Simple Science

Cutting edge science explained simply

# Biology# Neuroscience

Noradrenaline's Role in Decision-Making Based on Past Experiences

Study reveals how noradrenaline affects decision-making influenced by past choices.

Jan Willem de Gee, N. A. Kloosterman, A. Braun, T. H. Donner

― 5 min read


Noradrenaline andNoradrenaline andDecision Biaschoice history bias.Study reveals noradrenaline's effect on
Table of Contents

Humans often make decisions based on their past experiences, which can lead to biases. These biases appear in various types of judgments, including how we perceive our surroundings. For instance, if someone has successfully found food in a particular area before, they might choose to return to the same spot, even if conditions have changed. Research shows that the brain can adapt its expectations based on previous experiences, helping to improve Decision-making over time.

Despite understanding how this works, there's still a lot to learn about the brain's chemical systems that support these history-based biases. One chemical, Noradrenaline, has been suggested to play a key role in how past experiences influence our decisions. This article explores how increasing noradrenaline levels can impact the way we make choices based on our history.

The Role of Noradrenaline

Noradrenaline is a chemical in the brain that helps to regulate our responses and behavior. It is thought to reduce the significance of past experiences when learning and making decisions. This could be particularly useful when we're trying to compare new information with what we already know. The areas in the brain that use noradrenaline are connected to many regions involved in decision-making, meaning they can influence our choices across the brain.

In earlier studies, researchers looked at pupil size as an indirect measure of how aroused a person is. Changes in pupil size can indicate how the brain is processing information and adjusting its expectations. However, this method does not provide direct evidence about how noradrenaline affects decision-making based on past experiences, especially in humans.

Exploring the Effects of Atomoxetine

To investigate the link between noradrenaline and decision-making biases, scientists used a medication called atomoxetine. This drug is a selective noradrenaline reuptake inhibitor, meaning it increases the levels of noradrenaline in the brain by preventing its reabsorption. The goal was to see if this increase would reduce the influence of previous choices on new decisions.

Participants in the study took atomoxetine or a Placebo (a dummy pill) before engaging in a task where they had to identify which of two visual targets had a higher contrast. The study involved multiple trials to gather enough data for analysis. Researchers also monitored participants' heart rates and pupil sizes to measure arousal levels during the tasks.

Experimental Design

The experiment involved a series of visual tasks where participants had to indicate which of two targets they perceived as more prominent. Prior to the task, participants were given either the drug or a placebo. The task was designed to introduce uncertainty and encourage participants to integrate information over time.

Over several sessions, participants repeated the task under both conditions (drug and placebo). They received feedback on their choices, which helped them adjust their responses based on what they learned from previous trials. The study recorded both their actions and physiological responses, such as heart rate and pupil size.

Measuring Arousal and Decision-Making

When comparing the effects of atomoxetine to the placebo, researchers found that the drug did increase participants' heart rates and pupil sizes. This suggested that elevated noradrenaline levels made participants more alert but did not significantly change how quickly or accurately they made decisions.

Interestingly, atomoxetine did have a clear impact on how past experiences shaped choices. It reduced the tendency of participants to repeat their previous choices, moving their decision-making patterns closer to randomness. This indicated a reduction in choice history Bias, meaning participants were less likely to base their decisions solely on prior experiences.

Understanding Choice History Bias

During the placebo sessions, many participants exhibited a strong tendency to repeat their previous choices. This was reflected in their probability of selecting the same option as before. After taking atomoxetine, this statistic changed, showing that their decisions became less influenced by their recent choices.

The study's results indicated that atomoxetine reduced the participants' biases toward repeating or alternating choices, leading them closer to a random selection pattern. This shift suggests that elevating noradrenaline levels can help people make more balanced decisions without heavily relying on past experiences.

Evidence Accumulation in Decision-Making

In decision-making, people often accumulate evidence over time before making a choice. This process involves weighing information and reaching a conclusion when enough evidence is gathered. The research showed that the decrease in choice history bias after taking atomoxetine resulted from changes in how participants accumulated evidence.

Atomoxetine specifically reduced the influence of prior choices on the speed and strategy of evidence gathering. The findings suggested that participants began their decision-making process without the same biases they exhibited during the placebo session.

Conclusion

The study provides strong evidence that noradrenaline plays a significant role in regulating how past experiences influence our choices. By increasing noradrenaline levels with atomoxetine, participants displayed a reduced reliance on their previous experiences, demonstrating a more balanced decision-making approach.

This research sheds light on the complex interplay between our past experiences and current decision-making. Understanding these mechanisms can lead to insights into improving decision-making processes in various contexts, from everyday life to clinical settings. Through this research, we take a step closer to understanding how our brains function when faced with choices influenced by previous experiences.

Hopeful future studies can build on these findings, examining how other brain chemicals might interact with noradrenaline and how these interactions affect our behaviors and decisions. Overall, the insights gained from this research can pave the way for new strategies to enhance learning and decision-making in individuals, potentially benefiting a wide range of applications.

Original Source

Title: Catecholamines reduce choice history biases

Abstract: Theoretical accounts postulate that the catecholaminergic neuromodulator noradrenaline shapes cognitive behavior by reducing the impact of prior expectations on learning, inference, and decision-making. A ubiquitous effect of dynamic priors on perceptual decisions under uncertainty is choice history bias: the tendency to systematically repeat, or alternate, previous choices, even when stimulus categories are presented in a random sequence. Here, we directly test for a causal impact of catecholamines on these priors. We pharmacologically elevated catecholamine levels through the application of the noradrenaline reuptake inhibitor atomoxetine. We quantified the resulting changes in observers history biases in a visual perceptual decision task. Choice history biases in this task were highly idiosyncratic, tending toward choice repetition or alternation in different individuals. Atomoxetine decreased these biases (toward either repetition or alternation) compared to placebo. Behavioral modeling indicates that this bias reduction was due to a reduced bias in the accumulation of sensory evidence, rather than of the starting point of the accumulation process. Atomoxetine had no significant effect on other behavioral measures tested, including response time and choice accuracy. We conclude that catecholamines reduce the impact of a specific form of prior on perceptual decisions.

Authors: Jan Willem de Gee, N. A. Kloosterman, A. Braun, T. H. Donner

Last Update: 2024-10-28 00:00:00

Language: English

Source URL: https://www.biorxiv.org/content/10.1101/2024.10.28.620689

Source PDF: https://www.biorxiv.org/content/10.1101/2024.10.28.620689.full.pdf

Licence: https://creativecommons.org/licenses/by-nc/4.0/

Changes: This summary was created with assistance from AI and may have inaccuracies. For accurate information, please refer to the original source documents linked here.

Thank you to biorxiv for use of its open access interoperability.

More from authors

Similar Articles